Filter by:
Topic
Resource Type
Display Only
Showing 137 Results
In 2023, Decision Makers Should Dig into Data About Our Drug Pricing System
In Chain Drug Review, NPC's John O'Brien discusses how 2023 brings renewed imperative to root health policy decisions in evidence.
Shared Decision-Making Makes Sense for Patients and the Bottom Line
If shared decision-making is good for patients, is it good for the bottom line as well? A new study from NPC and Real Chemistry sheds light.
Impact of Shared Decision-Making and Patient Decision Aids on Health Care Cost and Utilization in the US: A Systematic Review
Shared decision-making and patient decision aids may reduce costs or improve utilization but not consistently across settings and diseases, according to a new systemic literature review by…
Characterizing Health Plan Evidence Review Practices
The study finds that some plans updated the evidence in their coverage policies for specialty medicines more often than others, and the type of evidence plans cited in their coverage policies…
Health Care Spending Effectiveness: Estimates Suggest that Spending Improved U.S. Health from 1996 to 2016
This research assessed the effectiveness of U.S. health care spending by comparing changes in health outcomes and found that, overall, innovations in health care are creating more cost-effective care…
Commentary: "New York Times Piece on Drug Market Ignores the Data (and Reality)"
NPC's President and CEO John M. O'Brien addresses research using politically expedient shortcuts and the consequences on policy...and patients.
NPC Comments on the Medicare Program's Hospital Inpatient Prospective Payment Systems
NPC's comments to CMS focus on recent proposals related to the transition to National Drug Codes for New Technology Add-on Payments and recommendations regarding payment mechanisms to improve access…
Health Care Spending Guiding Principles
NPC established a set of principles to assess health care spending estimates and policies to ensure alignment with the goals of patient-centered care.
NPC Creates Guiding Principles for Designing and Evaluating Health Care Spending Research and Policies
NPC has developed principles to help evaluate health spending research.
Case Study: Using Health Care Spending Guiding Principles to Evaluate "Will Reducing Drug Prices Slow Innovation"
NPC evaluated a study of drug pricing through the lens of its Health Care Spending Guiding Principles.
Patient-Centered Guiding Principles for Evaluating Health Care Spending
NPC established these principles to serve as a checklist to assess whether methods used for estimating health care spending are appropriate.
Patient-Centered Guiding Principles for Reforming Health Care to Address Rising Health Care Spending
NPC established these principles to assess health care spending policies to ensure alignment with the goals of patient-centered care.
New Moves to Shine More Light Into an Opaque Drug Pricing System
In his latest column for Chain Drug Review, NPC President and CEO John M. O’Brien points to the need for greater transparency in the pharmacy benefit manager-led rebate system.
Drug Price Regulation Trade-offs: Real or Imagined?
NPC hosted a panel at AcademyHealth’s National Health Policy Conference to explore the potential risks and unintended consequences of drug price regulation.
Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries
Proposals seeking to improve access for Medicare beneficiaries should ensure that patients are better able to get the medicines their doctors say they need.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
How Reforms Can Enable Payment Innovation That Drives Value
This NPC study models the effects of recent and proposed payment reforms related to CMS' best price reporting rules and sheds light on which approaches may encourage the adoption of value-based…
NPC in Chain Drug Review: Fostering a More Informed Drug Pricing Conversation
To kick off the new year, NPC's John M. O’Brien writes in Chain Drug Review about the need for a more informed public discussion about the role that prescription drugs play in our health care system…